| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2011: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Research Abstract |
We established EGFR-TKI-resistant non-small cell lung cancer (NSCLC) cell lines and found that these cell lines acquired collateral sensitivity to Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) (about 70 times) as compared with parental cell line. In parental PC-9, anti-tumor effect of TRAIL was restricted, because TRAIL activates not only apoptotic signaling but also anti-apoptotic signaling through Akt/NFkB activation by cross talk signaling from TRAIL receptor to EGFR. In case of the resistant cell lines that overexpressed c-MET, the crosstalk signaling from TRAIL receptor to c-MET was not observed, and TRAIL-mediated Akt/NFkB activation was quite diminished. From these observations, EGFR-TKI/TRAIL combination is thought to be useful therapy for NSCLC.
|
